Source:http://linkedlifedata.com/resource/pubmed/id/20064608
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2010-3-8
|
| pubmed:abstractText |
Arg-Gly-Asp (RGD) modified doxorubicin-loaded liposomes could improve anticancer effect, and vascular disrupting agents (VDAs) could induce a rapid and selective shutdown of the blood vessels of tumors. We propose that RGD-modified liposomes for co-encapsulation and sequential release of vascular disrupting agent combretastatin A-4 (CA-4) and cytotoxic agent doxorubicin (Dox) could enhance tumor inhibition responses. In this study, we encapsulated Dox and CA-4 in RGD-modified liposomes. The release rate of Dox was proved to be much slower than that of CA-4 in vitro. Flow cytometry and laser confocal scanning microscopy clearly showed that RGD-modification promoted intracellular uptake of liposomal drugs by B16/B16F10 melanoma tumor cells and human umbilical vein endothelial cells (HUVECs). Cytotoxicity assay showed that the IC(50) of RGD-modified liposomes was lower than that of the corresponding unmodified liposomes. Therapeutic benefits were examined on B16F10 melanoma tumors subcutaneously growing in C57BL/6 mice. In vivo study demonstrated that RGD-modified liposomes exhibited the most pronounced tumor regression effect when both CA-4 and Dox were co-encapsulated. These results suggest that the targeted drug delivery system for co-encapsulation of vascular disrupting agents and anticancer agents may be a promising strategy for cancer treatment.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Drug Carriers,
http://linkedlifedata.com/resource/pubmed/chemical/Drug Combinations,
http://linkedlifedata.com/resource/pubmed/chemical/Liposomes,
http://linkedlifedata.com/resource/pubmed/chemical/Oligopeptides,
http://linkedlifedata.com/resource/pubmed/chemical/Stilbenes,
http://linkedlifedata.com/resource/pubmed/chemical/arginyl-glycyl-aspartic acid,
http://linkedlifedata.com/resource/pubmed/chemical/combretastatin A-4
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
1873-3441
|
| pubmed:author | |
| pubmed:copyrightInfo |
(c) 2010 Elsevier B.V. All rights reserved.
|
| pubmed:issnType |
Electronic
|
| pubmed:volume |
74
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
467-73
|
| pubmed:meshHeading |
pubmed-meshheading:20064608-Animals,
pubmed-meshheading:20064608-Antineoplastic Agents,
pubmed-meshheading:20064608-Cell Culture Techniques,
pubmed-meshheading:20064608-Cell Line, Tumor,
pubmed-meshheading:20064608-Cell Survival,
pubmed-meshheading:20064608-Doxorubicin,
pubmed-meshheading:20064608-Drug Carriers,
pubmed-meshheading:20064608-Drug Combinations,
pubmed-meshheading:20064608-Drug Compounding,
pubmed-meshheading:20064608-Drug Delivery Systems,
pubmed-meshheading:20064608-Endothelial Cells,
pubmed-meshheading:20064608-Flow Cytometry,
pubmed-meshheading:20064608-Humans,
pubmed-meshheading:20064608-Liposomes,
pubmed-meshheading:20064608-Male,
pubmed-meshheading:20064608-Melanoma, Experimental,
pubmed-meshheading:20064608-Mice,
pubmed-meshheading:20064608-Mice, Inbred C57BL,
pubmed-meshheading:20064608-Oligopeptides,
pubmed-meshheading:20064608-Stilbenes,
pubmed-meshheading:20064608-Xenograft Model Antitumor Assays
|
| pubmed:year |
2010
|
| pubmed:articleTitle |
Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies.
|
| pubmed:affiliation |
State Key Laboratory of Natural and Biomimetic Drugs, Peking University Health Science Center, Beijing, China.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|